Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2028

Conditions

LymphomaFollicular LymphomaLymphoma,Non-HodgkinLymphoma, Non-Hodgkin's, Adult

Interventions

DRUG

Epcoritamab

Humanized IgG1 bispecific antibody, 5 or 60 mL vial, via subcutaneous (under the skin) injection per protocol.

Trial Locations (1)

RECRUITING

Beth Israel Deaconess Medical Center, Boston